Abstract 4754
Background
Breast cancer is the second leading cause of cancer deaths among women. Most women with breast cancer undergo surgery and chemotherapy and/or radiotherapy. These treatments trigger various side effects, for example, shoulder immobility, numbness or tightness, and lymphedema of the arm. Exercise-induced adaptations and better muscular performance may attenuate mentioned symptoms and side effects. The aim of this research is to determine whether there is correlation between physical exercise and the relief of symptoms predominating during radiotherapy.
Methods
Study was designed as a longitudinal sudy. The participants were female patients hospitalized at Department for Oncology at Clinical Hospital Centre Osijek, with diagnosed breast cancer, who were treated with radiotherapy after mastectomy. Research was conducted with an anonymous questionnaire, designed for the purpose of this study.
Results
There were total of 36 respondents. There was correlation between feeling of worry about the course of the disease in the beginning and the end of treatment with opinion that targeted exercises will reduce the worry (Spearman’s rho 0,630, P < 0,001). Also, there was correlation between with opinion that targeted exercises will reduce the anger and assessment that exercises reduced that feeling (Spearman’s rho 0,625, P < 0,001). After the treatment, most of the respondents evaluated the benefit from exercise in reducing pain, anger, fear and worry with 4 on a scale from 1 do 5, and they evaluated the feeling that exercises helped them with grade 5 on a scale from 1 do 5. The majority of respondents expressed that they will continue to exercise at home.
Conclusions
In general, respondents had good attitudes toward physical activity. Most of them exercise few times weekly and they think that exercise is useful. They strongly agreed that they would recommend the exercise to other patients who are suffering from this disease, that they feel that exercises helped them and that their attitude about the importance of exercise changed in a positive direction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3630 - Results of phase 1 clinical trial of high doses of Seleno-L-methionine (SLM) in sequential combination with Axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients
Presenter: Yousef Zakharia
Session: Poster Display session 3
Resources:
Abstract
2356 - Safety and Efficacy of CDX-014 , an Antibody-Drug Conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced Renal Cell Carcinoma
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
1028 - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz).
Presenter: Begona P. Valderrama
Session: Poster Display session 3
Resources:
Abstract
2293 - Effect of Antacid Intake on the Therapeutic Efficacy of Sunitinib (SUN) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts): a Sub-Analysis of the STAR-TOR Registry
Presenter: Katrin Schlack
Session: Poster Display session 3
Resources:
Abstract
1451 - Randomized phase 3 trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN Renal 101 Japanese subgroup analysis
Presenter: Motohide Uemura
Session: Poster Display session 3
Resources:
Abstract
4399 - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
Presenter: Jindrich Finek
Session: Poster Display session 3
Resources:
Abstract
1344 - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Presenter: Kyaw Thein
Session: Poster Display session 3
Resources:
Abstract
3462 - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
5268 - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
4235 - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES Study
Presenter: Cristina Masini
Session: Poster Display session 3
Resources:
Abstract